Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome

Jun 3, 2025Future cardiology

Semaglutide as an important medicine for managing combined heart, kidney, and metabolism problems

AI simplified

GLP-1 TherapiesGLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Semaglutide may reduce major adverse cardiovascular events (MACE) by 26% in high cardiovascular-risk patients with type 2 diabetes.

  • In type 2 diabetes, semaglutide improves glycemic control and slows chronic kidney disease progression.
  • The SUSTAIN-6 trial indicated a 26% reduction in MACE among patients taking semaglutide at doses of 0.5 or 1.0 mg weekly.
  • The FLOW trial found a 24% reduction in major kidney disease events with 1.0 mg semaglutide in individuals with type 2 diabetes and chronic kidney disease.
  • The SELECT trial demonstrated a 20% reduction in MACE with weekly 2.4 mg semaglutide in overweight or obese individuals with preexisting cardiovascular disease.
  • Semaglutide also alleviates heart failure symptoms and reduces hospitalizations in obese individuals, regardless of type 2 diabetes status.

AI simplified

Full Text

Full text is available at the source.
View full text ↗

Related papers

Nov '25
Semaglutide lowers heart problems in type 2 diabetes, with stronger benefits for people with chronic kidney disease
systematic review
Sep '24
Semaglutide's effects on heart failure in people with diabetes and kidney disease in the FLOW trial
top 1% journal
cited by 75 papers
randomized controlled trial
Nov '24
ANMCO Statement on Semaglutide for Heart, Kidney, and Metabolic Conditions
english abstract
Apr '25
GLP-1 and Dual GLP-1/GIP Treatments and Their Role in Heart, Kidney, and Metabolic Health
top 50% journal
cited by 2 papers
journal article
Apr '25
Possible effects of semaglutide 2.4 mg on people with obesity or overweight and heart disease: A study using data from the SELECT trial
top 5% journal
cited by 2 papers
journal article
Nov '25
Safety and Effectiveness of Semaglutide in People with Chronic Kidney Disease With or Without Type 2 Diabetes
top 20% journal
systematic review
Mar '25
Current understanding of semaglutide use in heart failure and artery disease
top 10% journal
journal article

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #28
Semaglutide linked to 74-fold higher risk of vision-threatening eye condition
6 days ago3 studies
issue #27
GLP-1 drugs linked to 18% lower risk of substance use disorders in 524,817 veterans
1 week ago7 studies
issue #26
86.5% of patients on semaglutide or tirzepatide lost at least 5% of body weight at 6 months in Medicaid study
2 weeks ago7 studies
issue #25
GLP-1 drugs linked to 20% lower dementia risk in diabetic kidney patients
3 weeks ago7 studies
issue #24
Tirzepatide beats semaglutide for weight loss by 6.1% in head-to-head comparison
4 weeks ago7 studies
issue #23
Bariatric Surgery vs. GLP-1s for cardiovascular risk
5 weeks ago7 studies
issue #22
GLP-1 drugs linked to better pregnancy rates in PCOS women and reduced cancer risk in diabetes patients
6 weeks ago7 studies
issue #21
GLP-1 drugs may fight addiction, and reduce alcohol consumption
7 weeks ago7 studies
issue #20
GLP-1 drugs show promise for kidney transplant patients and Alzheimer's, but may increase eye problems
8 weeks ago7 studies
issue #19
GLP-1 drugs cut heart attack risk by 22% vs competitors, but may increase vision loss risk
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief